|
WO2013162922A1
|
|
Taxane compounds, compositions and methods
|
|
US2009275654A1
|
|
Pharmaceutical Gallium Compositions and Methods
|
|
US2009275655A1
|
|
Pharmaceutical Gallium Compositions and Methods
|
|
EP2007203A2
|
|
Improved dosing and scheduling of oligomers
|
|
WO2007055885A2
|
|
Pharmaceutical gallium compositions and methods
|
|
US2006275308A1
|
|
Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
|
|
WO2006009549A1
|
|
Novel crystalline forms of compositions of matter including the elements gallium, nitrogen, and oxygen
|
|
AU2003300414A8
|
|
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
|
|
US7855183B2
|
|
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
|
|
US2005261366A1
|
|
Tri(alkylcarboxylato)gallium (III) products and pharmaceutical compositions containing them
|
|
ZA200301161B
|
|
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers.
|
|
AU2002241952A1
|
|
Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
|
|
US7795232B1
|
|
Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
|
|
US6060456A
|
|
Chimeric oligonucleoside compounds
|
|
US5955597A
|
|
Chirally enriched synthetic phosphate oligomers
|
|
US5877220A
|
|
Amide-based oligomeric cationic lipids
|
|
AU6649496A
|
|
Novel amide-based cationic lipids
|
|
AU6328796A
|
|
Phosphonic acid-based cationic lipids
|
|
CA2223088A1
|
|
Novel carbamate-based cationic lipids
|
|
EP0828749A1
|
|
Methods for the synthesis of organophosphorus derivatives
|
